Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Bristol-Myers Squibb Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (12)
Australian public assessment report (AusPar) (4)
Designation or determination (2)

Date

(-) 2017 (18)
2026 (4)
2025 (14)
2024 (6)
2023 (6)
2022 (18)
2021 (9)
2020 (15)
2019 (4)
2018 (23)
2016 (5)
2015 (14)
2014 (4)
2013 (7)
2012 (5)
2011 (10)
2010 (3)
2009 (3)
2007 (12)
2004 (1)

Search

Filters applied:

2017

Clear all

Sponsor content

18 result(s) found, displaying 11 to 18

MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c) of the Act

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 10/12.5 fosinopril 10mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 10/12.5 fosinopril 10mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets blister pack Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
MONOPLUS 20/12.5 fosinopril 20mg and hydrochlorothiazide 12.5mg tablets bottle Cancelled under s30(1)(c)

5 April 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd
AusPAR: Ipilimumab (rch)

23 February 2017

Australian public assessment report (AusPar)

Australian Public Assessment Report for Ipilimumab (rch)
Bristol-Myers Squibb Australia Pty Ltd - Organ preservation solution Cancelled under s41GL(d) of the Act

20 February 2017

Cancellation by sponsor

Requested by Bristol-Myers Squibb Australia Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.